- Conditions
- Prostate Cancer
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • South Weymouth, Massachusetts • Londonderry, New Hampshire
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 8,367
matching trials from the live ClinicalTrials.gov search.
- Conditions
- T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
- Interventions
- Rituximab, Etoposide, Siplizumab, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Ramucirumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 11
- States / cities
- San Francisco, California • Chicago, Illinois • Metairie, Louisiana + 8 more
- Conditions
- Pyoderma Gangrenosum
- Interventions
- Humira
- Drug
- Lead sponsor
- Wright State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Rituximab, Plasmapheresis
- Drug · Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 12
- States / cities
- Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more
- Conditions
- Breast Cancer, Lymphoma, Chemotherapy Effect
- Interventions
- Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
- Other
- Lead sponsor
- Carl Ade, M.S., Ph.D.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Manhattan, Kansas
- Conditions
- Prostate Cancer
- Interventions
- panitumumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Philadelphia, Pennsylvania
- Conditions
- Rheumatoid Arthritis
- Interventions
- Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
- Biological · Drug
- Lead sponsor
- Toray Industries, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Interventions
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Long-term follow-up
- Other
- Lead sponsor
- Shandong University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 50,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- GBM, Glioblastoma, Brain Tumor, Brain Tumor, Recurrent
- Interventions
- Abemaciclib, Bevacizumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Failing Renal Allograft
- Interventions
- Belatacept, Calcineurin inhibitor therapy, Mycophenolate mofetil, prednisone
- Drug
- Lead sponsor
- Andrew B Adams
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Ventilator-associated Pneumonia
- Interventions
- Daily SAT & SBT
- Procedure
- Lead sponsor
- Harvard Pilgrim Health Care
- Other
- Eligibility
- Not listed
- Enrollment
- 3,342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Salem, Massachusetts • St Louis, Missouri + 2 more
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
- Interventions
- Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ixabepilone, Carboplatin, Bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 13
- States / cities
- Fort Myers, Florida • Gainesville, Florida • Terre Haute, Indiana + 10 more
- Conditions
- Lung Cancer
- Interventions
- Nivolumab in combination with Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,041 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Lymphoma
- Interventions
- alemtuzumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
- Conditions
- Psoriasis
- Interventions
- adalimumab, MTX, placebo adalimumab, placebo MTX
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Abbott Park, Illinois
- Conditions
- Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Brentuximab, Bendamustine, Rituximab
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Heart Failure
- Interventions
- BVA-100
- Device
- Lead sponsor
- Daxor Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Glioblastoma
- Interventions
- CART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combination
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Casdozokitug, Atezolizumab, Bevacizumab, Placebo
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more